NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis $4.87 +0.38 (+8.46%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About OptimizeRx Stock (NASDAQ:OPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OptimizeRx alerts:Sign Up Key Stats Today's Range$4.47▼$5.0250-Day Range$3.83▼$8.1652-Week Range$3.78▼$16.65Volume758,036 shsAverage Volume351,982 shsMarket Capitalization$89.71 millionP/E RatioN/ADividend YieldN/APrice Target$10.42Consensus RatingModerate Buy Company OverviewOptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.Read More… Shocking footage from Bill Gates’ $100,000,000,000 AI Bet (Ad)If you missed out on Nvidia, watch this video I just made.Click here for full details. OptimizeRx Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks68th Percentile Overall ScoreOPRX MarketRank™: OptimizeRx scored higher than 68% of companies evaluated by MarketBeat, and ranked 286th out of 647 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOptimizeRx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about OptimizeRx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.35) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.02% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in OptimizeRx has recently increased by 4.80%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.02% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in OptimizeRx has recently increased by 4.80%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment0.41 News SentimentOptimizeRx has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 3 news articles for OptimizeRx this week, compared to 2 articles on an average week.Search Interest9 people have searched for OPRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.10% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptimizeRx's insider trading history. Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Stock News HeadlinesBrokerages Set OptimizeRx Co. (NASDAQ:OPRX) PT at $11.58November 19, 2024 | americanbankingnews.comOptimizeRx to Participate in Upcoming Investor ConferencesNovember 18, 2024 | globenewswire.comShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.November 23, 2024 | Brownstone Research (Ad)OptimizeRx price target lowered to $8 from $13 at StifelNovember 15, 2024 | markets.businessinsider.comOptimizeRx price target lowered to $8 from $16 at JMP SecuritiesNovember 15, 2024 | markets.businessinsider.comOptimizeRx (OPRX) Gets a Buy from Stifel NicolausNovember 15, 2024 | markets.businessinsider.comOptimizeRx Reports Strong Revenue Growth in Q3 2024November 14, 2024 | markets.businessinsider.comOptimizeRx: Buy Rating Affirmed Amid Financial Efficiency and Business Model ShiftNovember 14, 2024 | markets.businessinsider.comSee More Headlines OPRX Stock Analysis - Frequently Asked Questions How have OPRX shares performed this year? OptimizeRx's stock was trading at $14.31 at the start of the year. Since then, OPRX stock has decreased by 66.0% and is now trading at $4.87. View the best growth stocks for 2024 here. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) announced its earnings results on Tuesday, May, 14th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.16. The company had revenue of $19.69 million for the quarter, compared to the consensus estimate of $18.66 million. OptimizeRx had a negative trailing twelve-month return on equity of 4.92% and a negative net margin of 27.41%. Who are OptimizeRx's major shareholders? OptimizeRx's top institutional shareholders include Rice Hall James & Associates LLC (3.36%), Geode Capital Management LLC (2.16%), Essex Investment Management Co. LLC (1.32%) and Bullseye Asset Management LLC (1.17%). Insiders that own company stock include William J Febbo, James Paul Lang, Marion Odence-Ford, Stephen L Silvestro, Edward Stelmakh, Ellen O'connor Vos and Miriam J Paramore. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/14/2024Today11/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Business services, not elsewhere classified Sub-IndustryBusiness Services Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$10.42 High Stock Price Target$18.50 Low Stock Price Target$5.00 Potential Upside/Downside+113.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,570,000.00 Net Margins-27.41% Pretax Margin-37.84% Return on Equity-4.92% Return on Assets-3.41% Debt Debt-to-Equity Ratio0.29 Current Ratio3.23 Quick Ratio3.23 Sales & Book Value Annual Sales$88.18 million Price / Sales1.02 Cash FlowN/A Price / Cash FlowN/A Book Value$6.21 per share Price / Book0.78Miscellaneous Outstanding Shares18,421,000Free Float17,297,000Market Cap$89.71 million OptionableOptionable Beta1.32 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:OPRX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.